ArticleScientific reports2016
Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 106 citations in OpenAlex.
- Genetic Tools in the Nakaseomyces clade for Evolutionary Comparisons of Signal Transduction Pathways.Yeast (Chichester, England) · 2026Article
- Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.Molecular biotechnology · 2026Review
- EditingBiomolecules · 2026Review
- Natural product based approaches to overcomeFrontiers in antibiotics · 2026Review
- Exploring CRISPR/Cas9-Mediated Gene Editing Advances in Conventional and Non-conventional Yeast Species.Applied biochemistry and biotechnology · 2025Review
- CRISPR/Cas9-mediated genome editing in Ganoderma lucidum: recent advances and biotechnological opportunities.World journal of microbiology & biotechnology · 2025Review
- PCR-based CRISPR/Cas9 system for fluorescent tagging: A tool for studying Candida parapsilosis virulence.PloS one · 2025Article
- Advanced genetic techniques in fungal pathogen research.mSphere · 2024Review
- Article
- An expanded toolkit of drug resistance cassettes formSphere · 2023Article
- An Efficient CRISPR/Cas9 Genome Editing System for aJournal of fungi (Basel, Switzerland) · 2023Article
- 3Bs of CRISPR-Cas mediated genome editing in plants: exploring the basics, bioinformatics and biosafety landscape.Physiology and molecular biology of plants : an international journal of functional plant biology · 2023Review
- A Modular Cloning Toolkit Including CRISPRi for the Engineering of the Human Fungal Pathogen and Biotechnology HostACS synthetic biology · 2023Article
- Development and applications of a CRISPR activation system for facile genetic overexpression in Candida albicans.G3 (Bethesda, Md.) · 2023Article
- Split-marker-mediated genome editing improves homologous recombination frequency in the CTG clade yeast Candida intermedia.FEMS yeast research · 2023Article
- Use of CRISPR-Cas tools to engineer Trichoderma species.Microbial biotechnology · 2022Review
- RNA Interference (RNAi ) as a Tool for High-Resolution Phenotypic Screening of the Pathogenic Yeast Candida glabrata.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Superior Conjugative Plasmids Delivered by Bacteria to Diverse Fungi.Biodesign research · 2022Article
- CRISPR/Cas9 RNP-assisted validation of palmarumycin biosynthetic gene cluster inFrontiers in microbiology · 2022Article
- Plasmid-Based CRISPR-Cas9 Editing in Multiple Candida Species.Methods in molecular biology (Clifton, N.J.) · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among Candida species, the opportunistic fungal pathogen Candida glabrata has become the second most common causative agent of candidiasis in the world and a major public health concern. Yet, few molecular tools and resources are available to explore the biology of C. glabrata and to better understand its virulence during infection. In this study, we describe a robust experimental strategy to generate loss-of-function mutants in C. glabrata. The procedure is based on the development of three main tools: (i) a recombinant strain of C. glabrata constitutively expressing the CRISPR-Cas9 system, (ii) an online program facilitating the selection of the most efficient guide RNAs for a given C. glabrata gene, and (iii) the identification of mutant strains by the Surveyor technique and sequencing. As a proof-of-concept, we have tested the virulence of some mutants in vivo in a Drosophila melanogaster infection model. Our results suggest that yps11 and a previously uncharacterized serine/threonine kinase are involved, directly or indirectly, in the ability of the pathogenic yeast to infect this model host organism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.